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Summary
Background. The management of patients with small, often asymp-
tomatic meningiomas is controversial and includes observation, micro-
surgery (MS) and stereotactic radiosurgery (SRS). The purpose of this
retrospective study was to analyze the morbidity and the extent of re-
moval after MS for small (3 cm) intracranial meningiomas and com-
pare these results to those of SRS reported in the literature.
Methods. All patients with an intracranial meningioma with a max-
imum diameter up to 3 cm operated on in our institution over a 10 year
period (1992–2002) were included in the study and retrospectively
analyzed. Patients were grouped into asymptomatic and symptomatic
and according to tumor location as: group I (cranial vault, parasagittal,
lateral sphenoid), group II (falx, frontobasal, medial sphenoid, parasellar
and tentorial), group III (cavernous sinus, petroclival, petrosal, CPA and
foramen magnum).
Findings. There were a total of 201 patients, of whom 102 were
asymptomatic and 99 were symptomatic. The overall risk of permanent
neurological morbidity was 4.9% in asymptomatic and 23.2% in symp-
tomatic patients. The combined risk in asymptomatic and symptomatic
patients was 5.4% in group I, 11.5% in group II, and 39.9% in group III
lesions. Radical removal was achieved in all patients in group I, in
93.7% of group II, and 80% of group III lesions. There was no disease
related mortality.
Conclusions. MS provides excellent efficacy and morbidity results in
groups I and II meningiomas, especially in asymptomatic patients and
might therefore be considered the first choice of treatment for these
patients. The results of MS in group III were worse than those of SRS
reported in the literature.
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Introduction
The clinical presentation and management of patients
with meningiomas have changed significantly in the last
ten to fifteen years. First, the liberal use of computer
tomography and magnetic resonance imaging (MRI)
has led to diagnosis of more asymptomatic small and
medium sized tumors [30, 50]. Second, modern tech-
niques of radiation therapy, in particular stereotactic
radiosurgery (SRS), have been developed and are in-
creasingly being used to treat these lesions.
Meningiomas are typically treated primarily by sur-
gery [1–6, 9, 11–15, 17–19, 24, 29, 40, 42, 47–49, 52].
In recent years, SRS has gained an important role also as
a primary treatment option for meningiomas smaller
than 3 cm in diameter, mainly for those located in the
skull base [4–6, 8, 9, 11, 12, 14, 15, 17, 18, 20–22, 24,
25, 27, 28, 33, 35, 37, 40–46, 48, 49, 51, 52]. The
efficacy and the risks of MS are related to tumor size,
tumor location and to the pre-operative symptom status
[10]. However, data on the efficacy and morbidity of MS
for small tumors tend to be buried in series including all
tumor sizes and locations regardless of the pre-operative
symptom status [7, 24, 29, 34]. The results of most
surgical series are therefore not comparable to those in
radiosurgical reports. The uncertainties about the natural
course of the disease make also observation until clinical
and=or radiological progression to a reasonable manage-
ment option for small meningiomas, especially in asymp-
tomatic patients. The large majority of asymptomatic
patients monitored by serial scans will typically not be-
come symptomatic, even if their tumor grows. Also, it is
not demonstrated that the results of delayed treatment
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are worse than those of early treatment [34]. Tumor
growth is reported to occur in 12–43% of patients over
a mean observation period of 2.3–6.1 years [31]. The
growth rate may be variable over time and spans from
1 cm in diameter per year to no growth over years [16,
30–32, 34]. Some radiological characteristics may help
in the decision making: tumor calcifications are asso-
ciated with a low proliferative potential and may suggest
observation, whereas a lobulated shape or an irregu-
lar tumor surface associated with peritumoral edema
(hyperintensity in T2 weighted MRI) are associated with
high proliferative indices and might suggest treatment
upfront [31, 32].
Observation, MS, and SRS are therefore potentially
all reasonable management options in patients with
small intracranial, meningiomas. The purpose of our re-
trospective analysis was to provide data on the efficacy
and morbidity of MS for meningiomas theoretically
amenable to radiosurgical treatment, to analyze the data
according to tumor location and the pre-operative symp-
tom status, and to compare our surgical results with
radiosurgical data from the literature.
Patients and methods
All patients with a meningioma smaller or equal to 3 cm in diameter
operated on between 1992 and 2002 were included in this retrospective
study. Treatment strategy was defined by one of the authors (RWS) and
consisted in attempting radical removal of the tumor and of its dural
attachments whenever possible without sacrificing important structures,
the loss of which would entail worsening of a pre-existing or develop-
ment of a new neurological deficit. The operations were performed by or
under the supervision of the board certified staff. Outcome data were
assessed using the patient case-history chart, patient interviews, personal
physician interview and radiological studies.
Registered parameters
Demographic data, duration of the hospitalization and operation proce-
dure were noted. Maximum cross-sectional diameter of the meningiomas
was measured based on pre-operative scans. Meningiomas were further
categorized into three groups according to their location and the assumed
risk of resection and feasibility of radical removal (Table 1, Fig. 1).
Patients were categorized as being asymptomatic or symptomatic.
Surgical morbidity and mortality were registered for all patients and
analyzed according to the localization group. Morbidity lasting for more
than 6 months was recorded as permanent. Worsening of pre-operative
symptoms was also registered as surgical morbidity. Mortality occurring
within the 6 months following the intervention was registered as opera-
tion related, when a possible correlation was demonstrated. Complete
resection was defined as no visible tumor on postoperative scans. Resec-
tion was defined as incomplete whenever a residual tumor was visible on
postoperative imaging performed within the first three months after
surgery. All data were registered and processed in Access+ (Microsoft
Corporation, USA).
Histological diagnosis and tumor grading
The complete histological documentation of all cases was retrieved
from the files of the Institute of Pathology, University of Bern. All
microscopic slides were reviewed by a board certified neuropathologist
with special expertise in brain tumor pathology and classified according
to the current World Health Organization Classification of Tumors of the
Nervous System [26]. The issue of ‘‘brain invasive, otherwise benign’’
tumors was specifically addressed according to the criteria defined by
Perry et al. [36].
Statistical analysis
Statistical analysis was performed using two tailed Fisher’s Exact Test
for analysis of the group specific morbidity and the unpaired t-test for
analysis of the relationship between the pre-operative symptom status
and tumor size. The cut-off level for significance was set at p<0.05. The
statistical analysis was performed using SPSS+ 12.0 (SPSS, Chicago, IL,
USA) and InStat (Graphpad Software, San Diego, CA, USA). Data are
given in means  standard deviation, unless otherwise specified.
Results
A total of 201 patients harbouring a meningioma
smaller or equal to 3 cm in diameter were treated by
MS during the study period and were therefore included.
The mean age of 57.6 years was identical and the age
Table 1. Subgroup of meningioma according to location
Group I Group II Group III
convexity falx cavernous sinus
parasaggital frontobasal petroclival
lateral sphenoid medial sphenoid petrosal
parasellar cerebellopontine angle
tentorium foramen magnum
Fig. 1. Three dimensional drawing of the opened skull, showing the
three locations correlating with the surgical risk location: group I
(green), II (yellow) and III (red) in analogy to Table 1. (Adapted after
Meningiomas: Harvey Cushing 1938, Charles C Thomas Publisher,
with permission)
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distribution was not statistically different in asymptom-
atic and symptomatic patients (Fig. 2). One hundred
and fifty nine patients (79.1%) were female and 42
(20.9%) were male. The hospital stay was 10  3 days
for the whole study period. It dropped from 13.5 days in
1992 to 8 days in 2002. The operating time (skin to skin)
was 2.7 h  1.1, 3.9 h  1.3 and 4.9 h  1.7 in groups I,
II, and III, respectively.
WHO-grading
One hundred and ninety four meningiomas were
WHO grade I and 7 meningiomas were WHO grade II.
Of the latter, 4 were bonafide atypical meningiomas, and
3 were ‘‘brain invasive, otherwise benign’’ meningiomas
of either transitional or fibrous type. There was no loca-
tion group or symptom specific WHO grade distribution.
Fig. 2. Age distribution in asymptomatic and symptomatic patients. The mean age is identical in both categories (57.6 years)
Fig. 3. The overall tumor size in patients with asymptomatic menin-
giomas was significantly smaller than in the patients with symptomatic
meningiomas (p<0.001). The different sizes with their median and
standard deviation and the 95th percentile are given. The dots represent
the outliers
Table 2. Transient morbidities in asymptomatic and symptomatic
patients according to localization groups I–III
I II III
Asymptomatic
2 headache visual disturbance cerbrospinal fluid leak
bone flap instability abducens nerve palsy
respiratory distress facial nerve palsy
anosmia
seizure
bone flap instability
sinusitis
pneumonia
Symptomatic
2 facial numbness anosmia 3 cerebellar signs
2 paresthesias
right arm
2 hearing loss
and facial nerve
palsy ipsilatera
brainstem dysfunction
peripheral facial
nerve palsy
hearing loss 3 hearing loss
aphasia oculomotor
nerve palsy
2 facial nerve palsy
seizure hemiparesis 2 abducens nerve palsy
boneflap instability paresis leg amaurosis
leg thrombosis frontal brain
syndrome
3 facial hypesthesia
aphasia hypoglossal nerve palsy
2 cerebrospinal
fluid leak
visual disturbance
bone flap instability tuberculous meningio-
encephalitis
seizure pneumonia
meningitis
thrombosis leg
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Asymptomatic and symptomatic patients
One hundred and two patients were asymptomatic
before surgery, 99 were symptomatic. The mean size of
the meningiomas in asymptomatic patients was slightly
but significantly smaller than in symptomatic patients,
1.90  0.6 cm versus 2.25  0.6 cm, respectively (p<
0.001) (Fig. 3). Tumor location also differed between
asymptomatic and symptomatic patients. Among asymp-
tomatic patients there were 47 in group I, 48 in group II
and 7 in group III, whereas among symptomatic patients
26 were in group I, 47 in group II and 26 in group III.
Mortality
There was no mortality within 6 months after surgery
in the whole study group.
Morbidity
Transient neurological morbidity
The transient morbidity including all groups was
significantly lower in the pre-operatively asymptomatic
(12.7%) versus pre-operatively symptomatic patients
(43.4%, p<0.0001 for the difference). The relative risk
in pre-operatively asymptomatic patients to suffer tran-
sient morbidity was 8.5% (4=47), 16.6% (8=48) and
14.2% (1=7) in groups I, II, and III, respectively and
34.6% (9=26), 31.9% (15=47) and 73.0% (19=26) in
symptomatic patients. The nature of the transient mor-
bidity is specified in Table 2. and significances between
the groups are given in Table 3.
Permanent neurological morbidity
The permanent morbidity for all groups was signifi-
cantly lower in the pre-operatively asymptomatic (4.9%)
versus pre-operatively symptomatic patients (23.2%,
p<0.0001 for the difference) (Fig. 4). The risk of per-
manent morbidity in pre-operatively asymptomatic was
0% (0=47), 8.3% (4=48) and 14.3% (1=7) in groups I, II,
and III, respectively; the risk was 15.3% (4=26), 14.9%
(7=47) and 46.1% (12=26) in symptomatic patients (Fig.
4). The nature of the permanent morbidity is specified in
Table 4, and the significances between the groups are
given in Table 3.
Completeness of resection
Complete resection was achieved in 100% (47=47),
95.8% (46=48) and 71.4% (5=7) in asymptomatic groups
Table 3. Significance (p-values) of appearance of morbidity in patient subgroups between location groups I, II and III
Asymptomatic Symptomatic
Groups I II III I II III
Transient morbidity
Asymptomatic I x n.s. n.s.
II n.s. x n.s.
III n.s n.s. x
Symptomatic I x n.s. <0.01
II n.s. x <0.001
III <0.01 <0.001 x
combined asymptomatic and symptomatic
I II III
I x n.s. <0.001
II n.s. x <0.001
III <0.001 <0.001 x
Permanent morbidity
Asymptomatic I x <0.05 <0.01
II <0.05 x n.s.
III <0.01 n.s. x
Symptomatic I x n.s. <0.025
II n.s. x <0.01
III <0.025 <0.01 x
combined asymptomatic and symptomatic
I II III
I x n.s. <0.001
II n.s. x <0.001
III <0.001 <0.001 x
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I, II, and III, respectively (overall rate of complete resec-
tion 96.0%). In symptomatic patients complete resection
was achieved in 100% (26=26), 85.1% (40=47) and
80.7% (21=26) in groups I, II, and III respectively (over-
all rate of complete resection 87.8%) (Fig. 5 and
Table 5). Incomplete resection was significantly higher
in group III compared to group I, in both asymptomatic
(p<0.014) and symptomatic (p¼ 0.05) patients. A total
of 16 patients had incomplete resections (7.9%). Nine
patients showed no progression of the residual menin-
gioma. Seven patients necessitated secondary treatment
during the observation period of the study period, of
whom 5 patients with residual tumor received immediate
adjuvant radiotherapy and 2 patients received radio-
therapy after demonstration of progression. Two patients
had tumor recurrence after complete resection: one was
treated by surgery and the second by radiation therapy.
Discussion
In the present study of patients treated by MS for
meningioma, we included only tumors theoretically
amenable to radiosurgical treatment (smaller than 3 cm
in diameter). Pre-operative symptom status correlated to
the extent of tumor removal and with morbidity. Mor-
bidity was significantly higher in group III compared to
group I and group II patients. Also, in the subgroup of
asymptomatic patients there was a significantly higher
morbidity rate in group II compared to group I patients.
The correlation between outcome and pre-operative
symptom status and tumor locations in groups I, II and
III validated our classification and is therefore an impor-
tant finding. Classifying tumor locations according to
the estimated risk of surgery may be a matter of endless
debate. Also, our distinction between groups II and III
lesions is not always obvious since some tumors violate
the boundaries of these locations (e.g. an anterior clinoid
meningioma involving the cavernous sinus). Neverthe-
less, this classification is relatively simple and corre-
sponds to risk groups of MS according to our data. We
suggest that these classification criteria (pre-operative
symptom status and tumor location) should be consid-
ered for patients’ stratification in future studies compar-
ing MS and SRS.
Microsurgery in asymptomatic meningiomas
With a policy of removing any asymptomatic menin-
gioma at the time of diagnosis, we could achieve a com-
Fig. 4. Permanent morbidity in pre-operatively asymptomatic (upper
part) and symptomatic patients (lower part). The overall morbidity was
significantly increased in the symptomatic versus the asymptomatic
patients (p<0.0001)
Table 4. Permanent morbidity in asymptomatic and symptomatic
patients according to localization groups I–III
I II III
Asymptomatic
none abducens nerve palsy facial nerve palsy
boneflap instability
facial nerve palsy
anosmia
Symptomatic
2 facial numbness anosmia 2 cerebellar signs
2 paresthesias arm hearing loss brainstem dysfunction
oculomotor nerve palsy 3 hearing loss
paresis of the leg facial nerve palsy
hemiparesis abducens nerve paresis
frontal brain syndrome hypoglossal nerve palsy
seizure amaurosis
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plete removal in all convexity lesions (group I) without
permanent neurological morbidity. This figure could fa-
vour an aggressive surgical attitude in managing these
patients, since they are likely to be cured after surgery
and they do not need a long postoperative imaging fol-
low-up, which has obvious favourable consequences. Our
results were less good in patients with more deeply seated
tumors on the falx, tentorium, medial sphenoid wing and
frontal skull base (group II). Complete tumor removal
was possible in more than 96% but the toll in terms
of permanent morbidity was rather high (8.3% of the
patients). Only 7 of asymptomatic patients in our series
had tumors located in high-risk regions (petroclival, cer-
ebellopontine angle, foramen magnum). One patient suf-
fered permanent morbidity after surgery and two were
not amenable to complete resection. The present study
provides important figures of efficacy and morbidity in
asymptomatic patients with small meningiomas according
to the tumor location and may represent a reference for
future studies with which to contrast them.
Microsurgery in symptomatic meningiomas
In our series, the risk for permanent neurological def-
icits after surgery was significantly higher in symptom-
atic patients (overall risk 23.7%) compared to their
asymptomatic counterparts (4.9%), regardless of tumor
location. The difference may be in part related to the
larger size of symptomatic meningiomas and to the
higher proportion of group III lesions among symptom-
atic patients. In fact, the risk of surgery increased sig-
nificantly in more critical areas, in particular for tumors
in group III (46.1% compared to 15.3 and 14.9%, in
groups I and II, respectively). The association between
meningioma location and surgical outcome has already
been described by Harvey Cushing in his impressive
opus magnum [10]. In most series of the literature how-
ever, the analysis of morbidity was not performed
according to symptoms, tumor size and tumor location
which limits the comparability of the results. The rate of
15.3% new or worsened permanent morbidity for group
I lesions in the present series is relatively high. We did
not find a comparable series focussing on the results
obtained for symptomatic patients with convexity
meningioma (our group I) in the literature. Our 18.7%
rate of permanent morbidity in group II patients is com-
parable to that of Puchner et al., who published in 1998 a
series of 50 patients with suprasellar meningiomas and
reported 22% of permanent morbidity [40]. The high
rate of permanent morbidity (46.1%) in group III lesions
in the present series is also in accordance with the lit-
erature [3, 25, 41]. Roberti et al. reported a 41% rate of
permanent neurological deficits in a series of 161 menin-
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Fig. 5. Rates of complete and incomplete resection
over the groups I, II and III in asymptomatic and
symptomatic patients
Table 5. Distribution of number of cases according to the analysis
criteria: morbidity, symptoms, resection grade and tumor location
Permanent morbidities
Complete resection Incomplete resection
Asymptomatic I 0 out of 47 na
II 4 out of 46 0 out of 2
III 1 out of 5 0 out of 2
Symptomatic I 4 out of 26 na
II 4 out of 40 3 out of 7
III 8 out of 21 4 out of 5
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giomas in the posterior fossa [41]. In a similar location,
Bassiouni et al. reported a 9.8% rate of permanent facial
palsy, a deterioration of the hearing function in 18.4%,
and an additional 16% postoperative permanent neuro-
logical morbidity, thus a permanent morbidity rate of
44.2% [3]. Lobato et al. reported a 67.5% rate of tran-
sient neurological morbidity, with subsequent improve-
ment in most cases, in a series of posterior fossa
meningiomas [25]. No exact figures were provided for
permanent morbidity.
The completeness of resection was lower in symptom-
atic (85.1%) compared to the asymptomatic patients
(95.8%) in group II. The reason for this difference, that
did not reach statistical significance, is unclear.
A comparison with the radiosurgery data
from the literature
Since intracranial tumors treated by SRS are usually
smaller than 3 cm, our results may be compared with
those of radiosurgical series. However, the comparison
between retrospective radiosurgical and surgical series
has critical limitations. Radiosurgical series invariably
include a larger proportion of skull base meningiomas
and a lower number of superficial lesions compared to
surgical series (Table 6). Deep and superficial lesions
differ in several important aspects, like the clinical pre-
sentation (e.g. cranial nerve deficit and epilepsy), in the
sensitivity of the adjacent neural tissue to ionizing radia-
tions and potentially also in their biology.
In their series of 219 cases of meningiomas treated
with the gamma knife and diagnosed with imaging
criteria alone, Flickinger et al. reported an overall inci-
dence of postradiosurgical injury of 8.8%. An improve-
ment from 22.9 to 5.3% was registered over time, and
was attributed to the shift from a CT- to an MRI-based
dosage planning. The actuarial tumor control rate was
93% at both 5 and 10 years. Forty-five percent of the
tumors were located in the cavernous sinus or in the
petroclival region [14]. In a series of cavernous sinus
meningiomas treated by SRS, Pollock et al. reported a
morbidity rate of 13.7 and a 100% tumor control rate
[38]. In the series of Kondziolka et al. with 85 patients
harbouring a meningioma, 5 patients (6.1%) were re-
ported to suffer permanent morbidity using the same
criteria as in the present study [21, 23]. In a LINAC-
SRS based study, Friedman et al. reported transient com-
plications in 6.2% and permanent complications in 2.3%
of 210 meningioma patients [15]. If one considers that a
large proportion or even the majority of the tumors in
radiosurgical series are located in the skull base, one can
easily conclude that SRS provides better results than MS
for this group of patients, especially for those with a
group III meningioma. In fact, for these lesions the mor-
bidity of surgery is excessively high (46% in the present
study) and the resection is often incomplete (in approxi-
mately 80% of the patients in the present series).
These conclusions can not be generalized for all
patients with small meningiomas. Our best results were
obtained in group I tumors, especially in asymptomatic
patients. The overall rate of permanent neurological
morbidity of 5% (4=73 patients) in that group is compa-
rable to that of modern radiosurgical series. All 73
patients (asymptomatic and symptomatic patients with
small convexity meningiomas) were potentially cured,
although we do not provide long-term follow-up on
the rate of recurrence, which is a clear limitation of
the present series. Kim et al. specifically addressed the
question of GKS of small superficial convexity menin-
giomas and reported a high complication rate of 43%
Table 6. The overall percentage of permanent morbidity in series of microsurgically (MS) and with stereotactic radiosurgery (SRS) treated
meningiomas reported in the literature arranged according to our localization groups (I–III)
Author Year MS=SRS Number of patients Localization I, II, III % of permanent morbidity
Puchner et al. 1998 MS 50 II 22%
Roberti et al. 2001 MS 161 III 41%
Bassiouni et al. 2004 MS 51 III 44.2%
Lobato et al. 2004 MS 80 III na (67.5% transient)
Pollock et al. 2005 MS 136 (I), II, III 22.0%
Reinert et al. 2006 MS 201 I, II, III 5.4% (I), 11.5% (II), 39.9% (III)
Kondziolka et al. 1999 SRS 85 (II), III 6%
Flickinger et al. 2003 SRS 219 (II), III 8.8%
Pollock et al. 2003 SRS 38 III 13.70%
Pollock et al. 2005 SRS 62 (I), II, III 10%
Friedmann et al. 2005 SRS 210 (I), II, III 2.30%
Localization of the meningiomas were standardized according to the localization criteria used in the present report (see Table 1).
Localization group in parenthesis () means less than 5% of cases. Localization in bold means more than 75% of cases.
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(10=23 patients) with headache in all 10 and hemiparesis
in three cases [20]. Postirradiation peritumoral edema
was found in all cases. The symptoms appeared 1 to 12
months after SRS and resolved after steroids. Flickinger
et al. did not provide the specific rate of complica-
tions and the size of the tumors in their subgroup of
superficial meningiomas (81 patients according to our
calculation) [14]. They reported a total of 12 patients with
radiosurgical complications: 4 with edema and head-
ache, 2 with hemiparesis, 2 with mental changes, 3 with
trigeminal dysfunction and 1 with a temporary visual
deficit. A significant proportion of that morbidity might
have occurred in patients with superficial meningiomas.
Pollock et al. reviewed 198 patients with a newly diag-
nosed meningioma smaller than 35 mm in average diam-
eter who were treated by MS (n¼ 136) or SRS (n¼ 62)
between 1990 and 1997. The authors underscored two
aspects of their results: 1) the excellent tumor control
rate of SRS (actuarial progression-free survival of 95%
at 7 years) compared to radical MS (actuarial progres-
sion-free survival of 96% at 7 years in 57 patients with
Simpson grade 1 resections,); and 2) the lower overall
morbidity of SRS compared to MS (10 versus 22%,
p¼ 0.06) [39]. However the two treatment groups (SRS
and MS) were different: there were significantly more
cranial nerve deficits and skull base meningiomas in the
radiosurgical group compared with the surgical group.
Vice versa, there were more epileptic seizures and con-
vexity lesions in the surgical group compared with the
SRS group. This selection bias does not allow any con-
clusion about which method is superior e.g. for the treat-
ment of convexity meningiomas. Important aspects of
efficacy, e.g. epilepsy control, and of morbidity, e.g.
edema and cortical dysfunction, are indeed strongly re-
lated to tumor location and can only be addressed in
appropriately designed studies [24].
Conclusion
The clinical implications of our findings and of those
in the literature are not clear cut. It is reasonable to
observe some asymptomatic patients until evidence of
tumor growth prior to treatment, especially if the menin-
gioma is calcified and the patient is old. In terms of
efficacy and procedure related morbidity, the results of
microsurgical treatment of small sized (<3 cm) menin-
giomas strongly depends on tumor location and on the
pre-treatment symptom status at diagnosis. The results
of surgery are excellent for convexity lesions (group I).
It seems therefore appropriate to propose surgery to
patients with growing or symptomatic small convexity
meningiomas as a first-line treatment. The histological
verification of the tumor and its radical removal are
obvious advantages of surgery in these patients. The
results of surgery are fair for group II lesions (falx,
frontal skull base, tentorium, medial sphenoid wing,
parasellar), especially in asymptomatic patients. Some
of these lesions are in contact with structures with a
low tolerance to radiation (e.g. the optic nerves and
chiasm), suggesting that MS might still be the treatment
of choice. The results of MS are worse in group III
lesions (petrous apex, clivus, cavernous sinus, cerebel-
lopontine angle) where aggressive microsurgical treat-
ment has a rate of permanent neurological morbidity
up to 50% in symptomatic and up to 15% in asymptom-
atic patients.
Comparative studies assessing the relative potential of
MS versus SRS for subgroups of patients with small
meningiomas are lacking. However, data from the litera-
ture indicate that SRS is likely to yield results superior
to those obtained by MS in patients who are at high
surgical risk, such as the majority of patients with skull
base meningiomas.
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Comment
Primary treatment of small (30 mm) meningiomas – microsurgery
(MS) or stereotactic radiotherapy (SRT) given in one session (‘radio-
surgery’ or SRS)? Small meningiomas are problematic in two ways.
Firstly, MRI and CT cover European aging populations and increasingly
disclose incidental meningiomas that are quite frequent in population,
found in 1.4% of autopsies [1]. Secondly, neurosurgeons have to admit
that, taken all variables together, there are cases which SRS serves
equally or better than MS – but which cases and in whose hands?
Personally, doing microsurgery and radiosurgery, the distinction is
clear in meningiomas that affect the optic nerve(s): primary MS in the
suprasellar (planum sphenoidale, tuberculum sellae, clinoid process)
meningiomas – fractionated SRT in the optic nerve sheath meningiomas.
I also favour MS in the foramen magnum meningiomas that dangerously
pinch eloquent neural tissue. In small convexity tumours, I resent the
idea of SRS over MS, if the patient has symptoms (e.g., epilepsy), or he
or she is expected to live long, or there is a hyperdense signal in the
adjacent brain in T2 images, or the meningioma is not calcified. Having
been the darling subject of many a neurosurgical congress over less
showy topics, meningiomas involving the cavernous sinus and the clival
area have become a grey area because MS, even in the best of hands,
appears to endanger the cranial nerves while tumour tissue often left
behind. In our population-based practice, we do not go inside the caver-
nous sinus but leave that compartment for postoperative or primary SRS.
In a retrospective analysis, the authors compared the results of MS in
small meningiomas in their institute (201 patients between 1992 and
2002) to those of SRS in the literature. This is not a randomized trial of
adequate power, nor free of selection if the author’s institute does not
hermetically serve a given population. Nevertheless, the authors are to be
congratulated for a purposeful analysis, with the presence of preopera-
tive symptoms (=þ) and the location (group I: convexity, parasagittal,
lateral sphenoid; group II: falx, frontobasal, medial sphenoid, parasellar,
tentorial; group III: cavernous sinus, petroclival, petrosal, CP angle,
foramen magnum) as the main variables. There was no mortality, and
MS provided excellent results in small groups I and II meningiomas –
which are what we should expect from the European services. In small
group III meningiomas, however, permanent neurological morbidity
developed in 40%, and the removal was not complete in 20%.
This is a timely analysis to be further masticated by the microsurgeons
and the radiosurgeons – future skull base neurosurgeons should master
the both roles. Cell and molecular biology should reveal targets for
future therapies that would take care of the worst of meningiomas.
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